Endpoints 100 survey: Biotech CEOs predict MFN maneuvering and offer a few ideas for the FDA

Endpoints 100 1H 2026 CEO survey: optimism rebounds on hot M&A and IPOs; 64% see MFN delaying ex-US filings as execs demand a stable, faster FDA.

Raccontata daendpoints.news